Price transparency: A threat or an opportunity for affordable medical treatments?

How to cite

Ziegler, Andreas; Retel, Valesca; Harten, Wim van; Offerman, Theo; Romagnoli, Giorgia; Franzen, Nora. 2021. "Price transparency: A threat or an opportunity for affordable medical treatments?." AEA RCT Registry. AEARCTR-0007230. https://doi.org/10.1257/rct.7230-1.0

Download: BibTeX · RIS — for reference managers without a browser translator. Zotero and most others pick up this page's citation metadata directly.

Andreas Ziegler* , Valesca Retel , Wim van Harten , Theo Offerman , Giorgia Romagnoli , Nora Franzen

* Primary investigator

Registry ID
AEARCTR-0007230
DOI
https://doi.org/10.1257/rct.7230-1.0
First registered
Last updated
Status
In development
Trial dates
2021-02-23 – 2021-07-31
Countries
Germany (), Spain (), Netherlands (), Poland ()
JEL codes
C90, I11, L11, O30
Registry record
http://www.socialscienceregistry.org/trials/7230

Abstract

Access to affordable medical treatments may be endangered by the current bargaining system, in which the prices countries pay remain secret. Proponents of price confidentiality claim that it enables price cuts for poorer countries. In a laboratory experiment, we provide empirical evidence on the effects of price transparency in bargaining.

Experimental design

Experimental markets with 4 countries (representing The Netherlands, Germany, Poland, Spain) and one pharmaceutical company.

Three treatments: (1) price secrecy, where countries cannot share prices with other countries; (2) price transparency, where countries can share prices and observe other countries' prices; (3) full transparency, where in addition to price transparency, countries learn the company's R&D cost.

Design details

Randomization method
We implemented two die rolls for ordering of treatments. Treatment orders are for the first sessions: T2, T3, T1. For the second sessions: T1, T2, T3.
Randomization unit
Randomization of the treatment at a session level.
Clusters
26 market groups per treatment. This is the targeted number of groups. As this is an online experiment involving multiple labs, we recruit such that this number is reached, but better or worse than expected show-up or drop-outs may influence the number of groups per treatment. We randomize in advance the treatment assignment, and have recruitment balanced across treatments.
Observations
5 participants per market group per treatment, so 390 participants.
Arms
Per treatment, 130 participants in 26 market groups.
Primary outcomes
See the analysis plan.
Sponsors
Name: Netherlands Cancer Institute Location: Amsterdam, the Netherlands Url: https://www.nki.nl Name: Amsterdam Center for Behavioral Change Location: University of Amsterdam, the Netherlands Url: https://ase.uva.nl/research/amsterdam-center-for-behavioral-change/amsterdam-center-for-behavioral-change.html

Cited by

No citation data available for this registration yet.

Keywords